Foxp3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 432-438

  Schneider, Thomas ^a   Kimpfler, Silvia ^b   Warth, Arne ^c   Schnabel, Philipp A ^c   Dienemann, Hendrik ^a   Schadendorf, Dirk ^d   Hoffmann, Hans ^a   Umansky, Viktor ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Lung cancer; Lymph nodes; NK cells; Tumor microenvironment

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE; LYMPH NODE METASTASIS; MALE; NATURAL KILLER CELL; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT;

EID: 79951770388     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820b80ca     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Sakaguchi S. Regulatory T cells: key controllers of immunologic selftolerance. Cell 2000;101:455-458.
3. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
4. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology 2009;128:151-163.
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 1057-1061. (Pubitemid 36222930)
6. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-145. (Pubitemid 44401498)
7. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108: 804-811. (Pubitemid 44154611)
8. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-4408. (Pubitemid 37248397)
9. Esendagli G, Bruderek K, Goldmann T, et al. Malignant and nonmalignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008;59:32-40.
10. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-1723. (Pubitemid 27260108)
11. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-447.
12. Sobin LH, Gospodarowicz MK, Wittekind C (Eds.). TNM Classification of Malignant Tumors (International Union Against Cancer), 7th Ed. New york: Wiley-Blackwell, 2009. Pp. 136-146.
13. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-3133. (Pubitemid 29316012)
14. Fujimoto S, Greene M, Sehon AH. Immunosuppressor T cells in tumor bearing host. Immunol Commun 1975;4:201-217.
15. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-5380. (Pubitemid 46623168)
16. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-8331. (Pubitemid 41746944)
17. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761. (Pubitemid 34921025)
18. Sasada T, Kimura M, Yoshida Y, et al. CD4-CD25- regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-1099. (Pubitemid 37022112)
19. Yang Q, Goding SR, Hokland ME, et al. Antitumor activity of NK cells. Immunol Res 2006;36:13-25. (Pubitemid 46398589)
20. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004;5:996-1002. (Pubitemid 41057716)
21. Ghiringhelli F, Menard C, Martin F, et al. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006;214:229-238. (Pubitemid 44707914)
22. Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4-CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124:151-157. (Pubitemid 40269816)
23. Hiura T, Kagamu H, Miura S, et al. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005;175:5058-5066. (Pubitemid 41456389)
24. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4-CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453. (Pubitemid 38924326)
25. Knol AC, Lemaitre F, Pandolfino MC, et al. Absence of amplification of CD4-CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients. Exp Dermatol 2008;17:436-445. (Pubitemid 351513958)
26. Matsuura K, Yamaguchi Y, Ueno H, et al. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 2006;106:1227-1236. (Pubitemid 43363898)
27. Topol M, Maslon A. The problem of direct lymph drainage of the bronchopulmonary segments into the mediastinal and hilar lymph nodes. Clin Anat 2009;22:509-516.
28. Schirren J, Bergmann T, Beqiri S, et al. Lymphatic spread in resectable lung cancer: can we trust in a sentinel lymph node? Thorac Cardiovasc Surg 2006;54:373-380. (Pubitemid 44519266)
29. Ishibashi Y, Tanaka S, Tajima K, et al. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 2006;15:1315-1319.
30. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3- regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-2872. (Pubitemid 44937041)